Paolo Strati, M.D.
Department of Lymphoma and Myeloma, Division of Cancer Medicine
In the News
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2008 | Vita-Salute San Raffaele University, Milan, ITA, MD, MD |
Postgraduate Training
| 2016-2019 | Clinical Fellowship, Hematology-Oncology, MD Anderson, Houston, TX |
| 2014-2016 | Clinical Residency, Internal Medicine, Mayo Clinic, Rochester, MN |
| 2014-2014 | Research Fellowship, Malignant Hematology, Queen Mary University, Barts Cancer Institute, London |
| 2012-2014 | Clinical Fellowship, Leukemia (associated with Lymphoma during the 2nd year), MD Anderson Cancer Center, Houston, TX |
| 2010-2010 | Observership, Leukemia, MD Anderson, Houston, TX |
| 2009-2012 | Clinical Residency, Internal Medicine, San Raffaele Hospital, Milan |
| 2008-2009 | Clinical Internship, San Raffaele Hospital, Milan |
Board Certifications
| 2019 | American Board of Hematology, MD Anderson Cancer Center, Houston, TX |
| 2019 | American Board of Medical Oncology, MD Anderson Cancer Center, Houston, TX |
| 2016 | American Board of Internal Medicine, Mayo Clinic, Rochester, MN |
| 2014 | Italian Board of Internal Medicine, Vita-Salute San Raffaele, Milan, Italy, |
Experience & Service
Academic Appointments
Assistant Professor, Department of Internal Medicine, Mayo Clinic, Rochester, MN, 2016 - Present
Other Appointments/Responsibilities
Clinical Researcher, Lymphoma clinical research, Lymphoma Department, MD Anderson Cancer Center, Houston, TX, 2016 - Present
Clinical Researcher, Leukemia clinical research, Leukemia Department, MD Anderson Cancer Center, Houston, TX, 2016 - Present
Clinical Researcher, CLL clinical research, Division of Hematology, Mayo Clinic,, Rochester, NY, 2014 - 2016
Clinical Researcher, CLL and Lymphoma clinical research, Haemato-Oncology Department, Barts Cancer Centre, London, 2014 - 2014
Clinical Researcher, Lymphoma clinical research, Lymphoma Department, MD Anderson Cancer Center,, Houston, TX, 2013 - 2014
Clinical Researcher, Leukemia clinical research, Leukemia Department, MD Anderson Cancer Center,, Houston, TX, 2012 - 2014
Clinical Researcher, Lymphoma clinical research, Lymphoma Unit, San Raffaele Hospital,, Milan, Italy, 2010 - 2012
Clinical Researcher, Lung Cancer clinical research, Lung Cancer Unit, San Raffaele Hospital,, Milan, Italy, 2009 - 2010
Research Intern, Cancer Immunology, Pathology Department, San Raffaele Hospital,, Milan, Italy, 2007 - 2008
Clinical Researcher, Val Borbera Genetic Research Project, Vita-Salute San Raffaele University,, Milan, Italy, 2006 - 2009
Research Intern, Iron Metabolism, Center of Iron Metabolism Disorders, Vita-Salute San Raffaele University, Milan, 2006 - 2007
Research Intern, Genic Therapy, Center of Genic Therapy, Vita-Salute San Raffaele University,, Milan, 2004 - 2005
Honors & Awards
| 2019 | Waun Ki Hong Award Achievement in Clinical Investigation, Houston, TX |
| 2019 | AACR Molecular Biology in Clinical Oncology Workshop, Snowmass Village, CO,, AACR |
| 2019 | The Kimberly Patterson Fellowship in Leukemia Research Award, Houston, TX, |
| 2019 | Conquer Cancer Foundation of ASCO Merit Award, Chicago, IL, |
| 2019 | Clinical Education’s Resident/Fellow Excellence Award for Professionalism, Houston, TX |
| 2019 | Lymphoma Research Foundation Career Development Award, New York, NY |
| 2018 | Lymphoma Research Foundation Mentoring Program Scholar, New York, NY |
| 2018 | Abstract Achievement Award, American Society of Hematology, San Diego, CA, |
| 2018 | ASCO/FDA Fellow’s Day Workshop, Silver Spring, MA, |
| 2018 | Society for Translational Oncology Forum, Rising Star in Oncology Award, Leesburg, VA, |
| 2018 | Texas Society of Clinical Oncology, Outstanding Fellow Award, Houston, TX, |
| 2018 | SWOG Lymphoma Committee, invited member, Chicago, IL, |
| 2018 | ASH Foundation Committee, invited member, Washington, DC, |
| 2018 | ASH Clinical Research Training Institute, La Jolla, CA, 2018 |
| 2018 | The Shannon Timmins Fellowship for Leukemia Research, Houston, TX, |
| 2018 | The Kimberly Patterson Fellowship in Leukemia Research Award, Houston, TX |
| 2018 | Conquer Cancer Foundation of ASCO Young Investigator Award, Chicago, IL, |
| 2018 | Conquer Cancer Foundation of ASCO Merit Award, Chicago, IL, |
| 2017 | ASCO/AACR Methods in Cancer Clinical Research Workshop, Vail, CO, |
| 2017 | The Accademia del Lincei Leukemia Research Award, Rome, Italy, |
| 2017 | The Kimberly Patterson Fellowship in Leukemia Research Award, Houston, TX, |
| 2016 | Promotion to Academic Rank of Assistant Professor, Rochester, MN, |
| 2016 | Mayo Outstanding Research Achievement Award, Rochester, MN, |
| 2015 | ABIM Special Consideration, Washington, DC, |
| 2015 | Merit Award, Young Investigator Meeting, International Workshop on CLL, Sydney |
| 2015 | Young Investigator Award, Society of Hematology and Oncology, Houston, TX |
| 2015 | Special Mention for Oncology Research, Fondazione Lorini, Milan, Italy, |
| 2015 | Best Research Poster Presentation, National ACP, Boston, MA, |
| 2015 | Best Italian Young Clinical Researcher, Angelo Minich Foundation, Venezia, Italy |
| 2014 | Finalist at Best Italian Hematologist under 40, Rome, Italy, |
| 2014 | Best Italian Young Researcher Award, Fondazione Berlucchi, Brescia, Italy, |
| 2013 | Celgene Future Leaders Award for Clinical Research in Hematology, New Orleans, LA, |
| 2013 | Merit Award, American Society of Hematology, New Orleans, LA, |
| 2013 | Finalist at the Campese Leukemia Award, ISSNAF, Washington, DC, |
| 2013 | Merit Award, Society of Hematology and Oncology, Houston, TX, |
| 2013 | Best Oral Presentation, Young Investigator Meeting, iwCLL, Cologne, Germany |
| 2013 | Merit Award, Young Investigator Meeting, International Workshop on CLL, Cologne, Germany |
| 2013 | Rounding Recognition for Impacting Patients’ Experience, MDACC, Houston, TX, |
| 2013 | Best Clinical Leukemia Fellow, MD Anderson Cancer Center, Houston, TX, |
| 2013 | Trainee Excellence Award, MD Anderson Cancer Center, Houston, TX, |
| 2013 | Merit award, European Hematology Association, Stockholm, Sweden, |
| 2012 | Merit Award, American Society of Hematology, Atlanta, GA, |
| 2012 | Merit Award, Society of Hematology and Oncology, Houston, TX, |
| 2009 | Scholarship for Academic Excellence, Inner Wheel Valtrompia, Brescia, Italy, |
| 2002 | Scholarship for Academic Excellence, San Raffaele University, Milan, Italy, |
Selected Publications
Peer-Reviewed Articles
- Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica 105(1):e26-e28, 2020. e-Pub 2019. PMID: 31073068.
- Gunther JR, Park C, Dabaja BS, Milgrom SA, Cruz Chamorro RJ, Medeiros LJ, Khoury JD, Garg N, Amini B, Steiner R, Nair R, Strati P, Westin JR, Lee HJ, Fowler N, Nastoupil L, Neelapu SS, Pinnix CC. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma 61(1):1-5, 2020. e-Pub 2019. PMID: 31373240.
- Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134(22):1951-1959, 2019. PMID: 31537528.
- Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
- Strati P, Ferrajoli A. Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach. Drugs Aging 36(9):841-851, 2019. e-Pub 2019. PMID: 31055788.
- Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
- Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol 98(7):1611-1616, 2019. e-Pub 2019. PMID: 31093708.
- Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6):E150-E153, 2019. e-Pub 2019. PMID: 30785215.
- Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers (Basel) 11(7), 2019. e-Pub 2019. PMID: 31248056.
- Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood 133(26):2800-2802, 2019. e-Pub 2019. PMID: 31101626.
- Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. PMID: 31076409.
- Strati P, Neelapu SS. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Curr Oncol Rep 21(5):38, 2019. e-Pub 2019. PMID: 30919158.
- Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A. Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. Leuk Lymphoma 60(2):535-537, 2019. e-Pub 2018. PMID: 29911929.
- Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma 60(2):507-510, 2019. e-Pub 2018. PMID: 29966471.
- Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica 104(2):e65-e67, 2019. e-Pub 2018. PMID: 30190343.
- Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
- Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
- Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103(9):e416-e418, 2018. e-Pub 2018. PMID: 29622656.
- Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma 59(7):1672-1676, 2018. e-Pub 2017. PMID: 29119847.
- Autore F, Strati P, Laurenti L, Ferrajoli A. Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica 103(6):931-938, 2018. e-Pub 2018. PMID: 29748447.
- Strati P, Jain N, O'Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc 93(5):651-664, 2018. PMID: 29728204.
- Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI. Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book 38:592-603, 2018. PMID: 30231316.
- Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
- Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109-121, 2018. e-Pub 2017. PMID: 29143068.
- Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2017. PMID: 29196178.
- Akcan T, Strati P, Yan M, Idowu M. A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge. Case Rep Hematol 2018:9079462, 2018. e-Pub 2018. PMID: 30647982.
- Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica 102(12):e494-e496, 2017. e-Pub 2017. PMID: 28798068.
- Strati P, Benton CB, Manshouri T, Zhang Y, Bove JE, Sanchez-Petitto G, Verstovsek S. JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. Leuk Res 63:53-55, 2017. e-Pub 2017. PMID: 29101828.
- Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol 92(9):924-928, 2017. e-Pub 2017. PMID: 28556489.
- Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, Cerhan JR, Slager SL, Shanafelt TD. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 178(3):394-402, 2017. e-Pub 2017. PMID: 28580636.
- Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE, Shanafelt TD. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol 178(1):99-105, 2017. e-Pub 2017. PMID: 28386906.
- Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
- Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol 96(5):733-738, 2017. e-Pub 2017. PMID: 28247057.
- Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
- Ho TP, Strati P, Chon TY. 65-Year-Old Man With Weight Loss and Progressive Acral Necrosis. Mayo Clin Proc 92(4):605-608, 2017. e-Pub 2017. PMID: 28238397.
- Strati P. Treatment for relapsed or refractory chronic lymphocytic leukaemia: an ongoing challenge. Lancet Haematol 4(3):e97-e98, 2017. PMID: 28257754.
- Strati P, Chaffee KG, Achenbach SJ, Slager SL, Leung N, Call TG, Ding W, Parikh SA, Kay NE, Shanafelt TD. Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. Haematologica 102(1):e22-e25, 2017. e-Pub 2016. PMID: 27634202.
- Kay NE, Strati P, LaPlant BR, Leis JF, Nikcevich D, Call TG, Pettinger AM, Lesnick CE, Hanson CA, Shanafelt TD. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. Oncotarget 7(48):78269-78280, 2016. PMID: 27861157.
- Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol 3(9):e407-14, 2016. e-Pub 2016. PMID: 27570087.
- Strati P, Gharaibeh KA, Leung N, Cosio FG, Call TG, Shanafelt TD. Solid organ transplant in individuals with monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. Br J Haematol 174(1):162-5, 2016. e-Pub 2015. PMID: 26436615.
- Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, Chaffee KG, Call TG, Shanafelt TD. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica 101(4):458-65, 2016. e-Pub 2016. PMID: 26819053.
- Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood 127(14):1752-60, 2016. e-Pub 2016. PMID: 26841802.
- Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica 100(9):1180-8, 2015. e-Pub 2015. PMID: 26088927.
- Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ. Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 15(7):420-7, 2015. e-Pub 2015. PMID: 25800543.
- Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126(4):454-62, 2015. e-Pub 2015. PMID: 26065657.
- Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma 56(6):1878-80, 2015. e-Pub 2014. PMID: 25311497.
- Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90(4):276-81, 2015. e-Pub 2015. PMID: 25530214.
- Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer 121(6):876-82, 2015. e-Pub 2014. PMID: 25410759.
- Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res 38(10):1212-6, 2014. e-Pub 2014. PMID: 25217891.
- Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
- Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z. Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma 55(6):1425-7, 2014. e-Pub 2014. PMID: 23987820.
- Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
- Strati P, Ferrajoli A, Lerner S, O'Brien S, Wierda W, Keating MJ, Faderl S. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55(4):828-33, 2014. e-Pub 2013. PMID: 23808813.
- Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373-80, 2014. e-Pub 2013. PMID: 24151050.
- Strati P, O'Brien S. Reply to myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 120(3):452, 2014. e-Pub 2013. PMID: 24151154.
- Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 2013. e-Pub 2013. PMID: 23943357.
- Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11; quiz 2920, 2013. e-Pub 2013. PMID: 23896412.
- Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 2013. e-Pub 2013. PMID: 23969309.
- Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122(5):734-7, 2013. e-Pub 2013. PMID: 23801633.
- Greaves WO, Verma S, Bisrat T, Strati P, Rahimi H, Paladugu AV, Luthra R, Patel KP, Medeiros LJ, Yao H, Pierce S, Bueso-Ramos CE, Verstovsek S. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma 54(7):1552, 2013. e-Pub 2012. PMID: 23121011.
- Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk 13(3):287-91, 2013. e-Pub 2012. PMID: 23123105.
- Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2012. PMID: 23115106.
- Strati P, Caligaris-Cappio F. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?. Curr Opin Oncol 23(5):455-60, 2011. PMID: 21681094.
- Camaschella C, Strati P. Recent advances in iron metabolism and related disorders. Intern Emerg Med 5(5):393-400, 2010. e-Pub 2010. PMID: 20424932.
- Strati P, Ahmed MAA, Fowler N, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. e-Pub 2019. PMID: 31601688.
- Lyapichev KA, Sukswai N, Strati P, Iyer SP, Medeiros LJ, Miranda RN. Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues. Ann Diagn Pathol 43:151398. e-Pub 2019. PMID: 31630065.
Abstracts
- Strati P, Adkins S, Nastoupil LJ, Westin JR, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Clinical Implications of Cytopenias Beyond Day 30 after Axi-cel Therapy in Patients with Relapsed/Refractory Large B-cell Lymphoma. iCML, 2019.
- Dabaja B, Gule-Monroe M, Gunther JR, Milgrom S, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Nastoupil LJ, Neelapu SS, Pinnix CC, Fowler NH. Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Involvement: Can MRI Patter Help Predicting Outcome?. iCML, 2019.
- Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic Value of Pre-Treatment PET Scan in Patients with Follicular Lymphoma Receiving Frontline Therapy. iCML, 2019.
- Strati P, Phansalkar K, Ahmed MA, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin J, Noorani M, Nastoupil LJ, Davis RE, Fowler NH, Neelapu SS. BR vs RCHOP as Initial Treatment for Advanced Stage Follicular Lymphoma: A Matched-Pair Analysis. EHA, 2019.
- Strati P, Alcedo Andrade PE, Sano D, Rao VA, Singh P, Miranda R, Gunther JR, Pinnix CC, Dabaja BS, Lee HJ, Steiner RE. Relapsed and Refractory Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): a US Analysis from MD Anderson Cancer Center. iCML, 2019.
- Gunther JR, Pinnix CC, Glober G, Lee HJ, Ahmed S, Steiner R, Nair R, Strati P, Neelapu SS, Nastoupil L, Dabaja BS. Partial Omission of Bleomycin for Patients with Early Stage Hodgkin Lymphoma Treated with Combined Modality Therapy: Does Incomplete ABVD Therapy Lead to Inferior Outcomes?. ASTRO, 2019.
- Strati P, Adkins S, Nastoupil LJ, Westin JR, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Varma A, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic Recovery and Immune Reconstitution after Axi-cel CAR T-cell Therapy in Patients with Relapsed/Refractory Large B-cell Lymphoma. ASCO, 2019.
- Strati P, Ahmed MA, Fowler NH, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Romaguera JE, Noorani M, Phansalkar K, Cheah C, Feng L, Davis RE, Nastoupil LJ, Neelapu SS. Prognostic Value of Baseline SUVmax in Patients with Advanced Stage Follicular Lymphoma Receiving Frontline Rituximab-Based Therapy. ASCO, 2019.
- Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Wistuba II, Burger JA.. Characterization of Bone Marrow Tumor-Associated Macrophages in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. AACR, 2019.
- Thompson PA, Srivastava J, Strati P, Jorgensen J, Hether T, Keating MJ, O’Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Undetectable-Minimal Residual Disease (U-MRD6) (10-6 sensitivity) is Associated with Best Progression-free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10-4 sensitivity) with First-line FCR. ASH, 2018.
- Strati P, Takahashi K, Keating MJ, Thompson PA, Hinojosa C, Rodriguez DR, Daver NG, Jain N, Burger JA, Estrov Z, O’Brien S, Wierda W, Kantarjian H, Futreal A, Ferrajoli A. Combination of Lenalidomide and Rituximab in Patients with Treatment-Naive and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response. ASH, 2018.
- Strati P, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Burger JA. Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. ASH, 2018.
- Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib Therapy Improves Renal Function in Patients with Primary Myelofibrosis. ASH, 2018.
- Strati P, Takahashi K, Wang F, Tambaro FP, Keating MJ, Ferrajoli A, Estrov Z, Thompson PA, Jain P, Bose P, Futreal A, Wierda W. The Landscape of Genetic Mutations in Patients with Chronic Lymphocytic Leukemia and Complex Karyotype. TxSCO, 2018.
- Strati P, Takahashi K, Wang F, Tambaro FP, Keating MJ, Ferrajoli A, Estrov Z, Thompson PA, Jain P, Bose P, Futreal A, Wierda W. The Landscape of Genetic Mutations in Patients with Chronic Lymphocytic Leukemia and Complex Karyotype. SOHO, 2018.
- Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Montillo M, Gentile M, Morabito F, Molica S, Falcucci P, D’Arena G, Murru R, Vincelli D, Efremov DG, Visentin A, Reda G, Tisi MC, Vitale C, Rigolin GM, Ferrajoli A, Laurenti L.. LDH as a Predictive Marker in Patients with CLL and Trisomy 12. SOHO, 2018.
- Strati P, Oki Y, Fayad LE, Nastoupil L, Fowler N, Hagemeister F, Kwak L, Lee H, Wang M, Westin J, Ruben CE, Wesson ET, Fanale MA.. The Combination of Romidepsin and Alisertib is a Safe and Effective Regimen for Relapsed/Refractory Hodgkin and T-cell Lymphomas: a Phase I Study. EHA, 2018.
- Strati P, Garcia-Manero G, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo C, Short N, Yilmaz M, Naqvi K, Pierce SA, Cortes J, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. EHA, 2018.
- Strati P, Garcia-Manero G, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo C, Short N, Yilmaz M, Naqvi K, Pierce SA, Cortes J, Kantarjian H, Ravandi F. Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts. ASCO, 2018.
- Strati P, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Burger JA. Achievement of Complete Remission (CR) is a Desirable Endpoint for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib. ASCO, 2018.
- Strati P, Burger JA, O’Brien SM, Wierda WG, Estrov Z, Zacharian G, Keating MJ, Ferrajoli A.. Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia. IACRLRD Symposium, 2017.
- Strati P, Oki Y, Fayad LE, Nastoupil L, Fowler N, Hagemeister F, Kwak L, Lee H, Wang M, Westin J, Ruben CE, Wesson ET, Fanale MA. A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas. ASH, 2017.
- Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O’Brien SM, Rezvani K, Kantarjian H, Burger JA, Hinojosa C, Keating MJ, Estrov Z.. Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia. ASH, 2017.
- Strati P, Burger JA, O’Brien SM, Wierda WG, Estrov Z, Zacharian G, Keating MJ, Ferrajoli A.. Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia. SOHO, 2017.
- Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Coscia M, Gozzetti A, Gentile M, Morabito F, D’Arena G, Murru R, Vincelli D, Padova D, Reda G, Vitale C, Ferrajoli A, Laurenti L.. LDH as predictive parameter in treatment-naïve patients with +12 chronic lymphocytic leukemia. EHA, 2017.
- Hu B, Wang F, Yuanqing Y, Kim E, Patel K, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Do KA, Keating M, Burger J, Ferrajoli A, Wierda W, Futreal A, Takahashi K.. Landscape of somatic mutations and their impact on response and outcomes from lenalidomide-based therapies in patient with chronic lymphocytic leukemia. EHA, 2017.
- Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Coscia M, Gozzetti A, Gentile M, Morabito F, D’Arena G, Murru R, Vincelli D, Padova D, Reda G, Vitale C, Ferrajoli A, Laurenti L.. Prognostic Study of clinic-biological characteristics in treatment-naïve patients affected by CLL with +12. iwCLL, 2017.
- Ferrajoli A, Strati P, Burger JA, O’Brien SM, Wierda WG, Estrov Z, Zacharian G, Keating MJ.. Consolidation Treatment with Lenalidomide Following Frontline or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia. iwCLL, 2017.
- Strati P, Keating MJ, Wierda WG, Estrov Z, Jain N, Burger JA, Hinoiosa C, Ferrajoli A.. Durable Responses are Observed in Patients with Chronic Lymphocytic Leukemia (CLL) after Discontinuation of Lenalidomide Treatment. iwCLL, 2017.
- Strati P, Thompson PA, Keating MJ, Hinojosa C, Rodriguez DL, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien S, Wierda WG, Ferrajoli A. A Phase II Study of the Combination of Lenalidomide and Rituximab as Frontline Treatment in Patients with Chronic Lymphocytic Leukemia. iwCLL, 2017.
- Alhuraiji A, Falchi L, Keating MJ, Estrov Z, Strati P, Wierda WG, Jain N, Thompson PA, Ferrajoli A.. Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes. ASH, 2016.
- Thompson PA, Strati P, Keating MJ, O’Brien SM, Ferrajoli A, Burger JA, Faderl S, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo C, Daver NG, Jabbour E, Wierda WG.. Early achievement of MRD-negativity in IGHV-mutated (IGHV-M) patients portends highly favorable outcomes after first-line treatment of CLL with fludarabine, cyclophosphamide and rituximab (FCR). Serial monitoring for minimal residual disease (MRD) in blood after achieving MRD-negativity predicts subsequent clinical relapse. ASH, 2016.
- Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Coscia M, Gozzetti A, Gentile M, Morabito F, D’Arena G, Murru R, Vincelli D, Padova D, Reda G, Vitale C, Ferrajoli A, Laurenti L.. LDH Levels Predict Progression-Free Survival in Treatment-Naive Patients with Trisomy 12 Chronic Lymphocytic Leukemia. ASH, 2016.
- Strati P, Bose P, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Bueso-Ramos CE, Verstovsek S.. Immature Platelet Fraction is Associated with JAK2 V617F Mutation and Features of Advanced Disease in Myelofibrosis. ASH, 2016.
- Strati P, Thompson PA, Keating MJ, Hinojosa C, Rodriguez DR, Wang X, Daver NG, Jain N, Burger JA, Estrov Z, O’Brien S, Wierda W, Kantarjian H, Ferrajoli A.. A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-naïve and Relapsed Chronic Lymphocytic Leukemia. ASH, 2016.
- Strati P, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Kay NE, Ding W, Parikh SA, Jelinek DF, Hanson CA, Shanafelt TD.. CD49d expression is associated with development of lymphadenopathy in patients with Monoclonal B-cell lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL). ASH LB, 2016.
- Strati P, Shanafelt TD, LaPlant BR, Pettinger AM, Lesnick CE, Nikcevich D, Call TG, Ding W, Hanson CA, Kay NE. Low Baseline CCL-3 and CCL-4 Levels Predict Response to Bevacizumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). ASH LB, 2016.
- Strati P, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Kay NE, Ding W, Parikh SA, Jelinek DF, Hanson CA, Shanafelt TD.. CD49d expression is associated with development of lymphadenopathy in patients with Monoclonal B-cell lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL). EHA, 2016.
- Strati P, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Kay NE, Ding W, Parikh SA, Jelinek DF, Hanson CA, Shanafelt TD. CD49d expression associates with small lymphocytic lymphoma (SLL) presentation of chronic lymphocytic leukemia (CLL). ASCO, 2016.
- Strati P, Shanafelt TD, LaPlant BR, Pettinger AM, Lesnick CE, Nikcevich D, Call TG, Ding W, Hanson CA, Kay NE.. The Addition of Bevacizumab to Chemoimmunotherapy Prolongs Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia (CLL) Through Modulation of the Microenvironment. AACR, 2016.
- Strati P, Chon TY. Atypical presentation of a Common Disease of the Elderly. MN ACP, 2015.
- Strati P, Uhm JH, Hanson CA, Chaffee KG, Achenbach SJ, Call TG, Shanafelt TD. Central Nervous System Involvement By Chronic Lymphocytic Leukemia. ASH, 2015.
- Strati P, Uhm JH, Hanson CA, Chaffee KG, Achenbach SJ, Call TG, Shanafelt TD.. Diagnostic Role of Lumbar Puncture (LP) for the diagnosis of Central Nervous System (CNS) Involvement by Chronic Lymphocytic Leukemia(CLL)/Richter Syndrome (RS). SOHO, 2015.
- Strati P, Gharaibeh KA, Leung N, Cosio F, Call TG, Shanafelt TD. Kidney Transplant (KT) in Individuals with Monoclonal B-cell lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL). IKMG, 2015.
- Strati P, Chaffee KG, AchenbachSJ, Schwager SM, Call TG, Kay NE, Cerhan JR, Slager SL, Shanafelt TD.. Disease Progression and Complications are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. iwCLL, 2015.
- Strati P, Uhm JH, Hanson CA, Chaffee KG, Achenbach SJ, Call TG, Shanafelt TD. Prevalence and Characteristics of Central Nervous System (CNS) disease involvement by Chronic Lymphocytic Leukemia (CLL). EHA, 2015.
- Strati P, Chaffee KG, Achenbach SJ, Slager SL, Schwager SM, Call TG, Leung N, Shanafelt TD.. Prognostic Impact of Renal Insufficiency (RI) at Diagnosis in Patients with Chronic Lymphocytic Leukemia (CLL). ASCO, 2015.
- Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD.. Renal Complications of Chronic Lymphocytic Leukemia/Monoclonal B-cell Lymphocytosis (CLL/MBL). National ACP, 2015.
- Strati P, Chaffee KG, Achenbach SG, Call TG, Kay NE, Cerhan J, Slager S, Shanafelt TD.. Comorbidity and cause of death in patients with chronic lymphocytic leukemia (CLL). AACR, 2015.
- Ciccone M, Vitale C, Hinojosa C, Keating MJ, Pemmaraju N, O'Brien S, Burger JA, Thomas DA, Kantarjian H, Strati P, Wierda WG, Ferrajoli A. Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL). ASH, 2014.
- Strati P, Patel P, Tosh J.. A Case of Vancomycin-Induced Thrombocytopenia. MN ACP, 2014.
- Abi Aad S, Daver N, Strati P, Cortes J, Garcia-Manero G, Mathisen M, Ravandi F, Kadia T, O'Brien S, Bivins C, Pierce S, Kantarjian H, Jabbour E. High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse. ASCO, 2014.
- Jabbour E, Kantarjian H, Strati P, Cortes J, O’Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Dinardo C, Daver N, Kadia T, Wierda WG, Wei Y, Colla S, Borthakur G, Estrov Z, Garcia-Manero G.. Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). ASH, 2013.
- Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J.. Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. ASH, 2013.
- Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A.. Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia. ASH, 2013.
- Strati P, Overman MJ, Fowler N, Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad LE. Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). ASH, 2013.
- Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH,Wierda WG. Bone Marrow (BM) May be More Informative than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL),. ASH, 2013.
- Strati P, Overman MJ, Fowler N, Romaguera JE, Kwak LW, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad LE. Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP). SOHO, 2013.
- Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH,Wierda WG. Bone Marrow (BM) May be More Informative than Peripheral Blood (PB) to Evaluate Minimal Residual Disease (MRD) During 1st and 2nd Year Follow up After First-line Fludarabine, Cyclophosphamide, and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL). SOHO, 2013.
- Strati P, Keating MJ, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for CLL patients with del17p. iwCLL, 2013.
- Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH,Wierda WG. Achieving Bone Marrow CLL MRD disease-free status with 1st-line FCR is associated with improved PFS and can be considered a primary treatment objective. iwCLL, 2013.
- Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). EHA, 2013.
- Strati P, Wierda W, Burger J, Ferrajoli A, Tam CS, Lerner S, Keating MJ, O’Brien S. Prolonged cytopenia related to FCR in CLL. EHA, 2013.
- Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH,Wierda WG. Achieving Bone Marrow CLL MRD disease-free status with 1st-line FCR is associated with improved PFS and can be considered a primary treatment objective. EHA, 2013.
- Strati P, Keating MJ, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for CLL patients with del17p. EHA, 2013.
- Strati P, Keating MJ, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for CLL patients with del17p. ASCO, 2013.
- Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). ASH, 2012.
- Strati P, Abruzzo LV, Wierda WG, O’Brien S, Ferrajoli A, Keating MJ. Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12. ASH, 2012.
- Strati P, Kantarjian H, Thomas D, O’Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi R, Cortes JE. HyperCVAD Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia. ASH, 2012.
- Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. ASH, 2012.
- Strati P, Kantarjian H, Thomas D, O’Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi R, Cortes JE. HyperCVAD Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia. SOHO, 2012.
- Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. ents with AcuBiological and Clinical Features of Patite Myeloid Leukemia Bearing Trisomy 21. SOHO, 2012.
- Lazzari C, Gregorc V, Filipski K, Strati P, Sparreboom A. Association of ABCC2 polymorphism with cisplatin disposition and efficacy. ESMO, 2010.
- Rossoni G, Strati P, Caligaris-Cappio F. Aggressive Mastocytosis and Guillain-Barre’ Syndrome. SIMI, 2007.
- Rossoni G, Strati P, Caligaris-Cappio F. Squamocellular Lung Cancer Stage IIIA Treated with Radiation Therapy Only. SIMI, 2007.
Book Chapters
- Strati P, Patel S, Nastoupil L, Michelle FA, Bollard CM, Lin AY, Gordon LI. Beyond Chemotherapy. In: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book, 2018.
- Caligaris-Cappio F, Camaschella C, Strati P. Emergencies in Hematology. In: Medicina D’Urgenza Pratica e Progresso, 2nd Edition. CGEMS, 2013.
Grant & Contract Support
| Title: | A Phase I/Ib Study of CC-90002, Lenalidomide and Rituximab for Patients with Relapsed B-NHL |
| Funding Source: | Lymphoma Research Foundation Mentoring Program |
| Role: | Principal Investigator |
| Title: | Characterization of the Tumor Microenvironment in Response to Novel Targeted and/or Immune Therapies in Patients with Follicular Lymphoma |
| Funding Source: | Institutional Start Up Grant |
| Role: | Principal Investigator |
| Title: | Combined CD47 Inhibition and Lenalidomide in Relapsed B-NHL: a Chemotherapy-Free Approach |
| Funding Source: | Institutional Research Grant |
| Role: | Principal Investigator |
| Title: | |
| Funding Source: | Giordano Foundation Grant |
| Role: | Principal Investigator |
| Title: | Grant period: 07/01/2018-12/31/2019 A Phase I/Ib Pilot Study of Combined Trabectedin and Venetoclax in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK inhibitor |
| Funding Source: | 12994 Conquer Cancer Foundation Young Investigator Award |
| Role: | Principal Investigator |
| Title: | |
| Funding Source: | Celgene Award as Future Leader in Hematology |
| Role: | Principal Investigator |
| Title: | Targeting Macrophage to Mitigate CAR-T Toxicity in B-cell Non-Hodgkin Lymphoma |
| Funding Source: | Lymphoma Research Foundation Career Development Award |
| Role: | Principal Investigator |